The firm’s revenue grew nearly 4.4% year-on-year but declined marginally sequentially by 0.9%, while its profit after tax was down 14% year-on-year and 16% quarter-on-quarter, as product-specific headwinds persisted.
Dr Reddy’s net profit beats estimates despite 14% dip, set for India semaglutide launch
📅 Published: January 21, 2026 |
📂 Category: Uncategorized
